methyl N-{N-[(E)-[(2-chlorophenyl)methylidene]amino]carbamimidoyl}carbamate | 1620238-01-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl N-{N-[(E)-[(2-chlorophenyl)methylidene]amino]carbamimidoyl}carbamate
• 英文别名: methyl N-[(E)-N'-[(E)-(2-chlorophenyl)methylideneamino]carbamimidoyl]carbamate
• CAS: 1620238-01-8
• 化学式: C₁₀H₁₁ClN₄O₂
• 分子量: 254.676
• InChiKey: MKXYOZCSVVKILZ-AWNIVKPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (E)-2-(2-chlorobenzylidene)hydrazine-1-carboximidamide 、 氯甲酸甲酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以37%的产率得到methyl N-{N-[(E)-[(2-chlorophenyl)methylidene]amino]carbamimidoyl}carbamate
  参考文献：
  名称：

  [EN] BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES
  [FR] DÉRIVÉS DE BENZYLIDÈNEGUANIDINE ET LEUR UTILISATION THÉRAPEUTIQUE POUR LE TRAITEMENT DE MALADIES LIÉES À UN MAUVAIS REPLIEMENT DE PROTÉINES

  摘要：

  本发明涉及一种具有以下结构的化合物（I），或其亪式和/或药用可接受的盐，其中：R1为烷基，Cl，F或Br；R2为H或F；R3从H和烷基中选择；R4从H和C（O）R6中选择；R5为H；或R4和R5连接形成一个杂环基团，该基团可以选择性地用一个或多个R10基团取代；R6从R7，OR7和NR8R9中选择；R7，R8和R9分别独立选择自烷基，环烷基，芳基，环烯基，杂环烷基和芳基，每个基团可以选择性地用一个或多个R10基团取代；每个R10独立选择自卤素，OH，CN，NO2，COO-烷基，芳基，SO2-烷基，SO2-芳基，COOH，CO-烷基，CO-芳基，NH2，NH-烷基，N（烷基）2，CF3，烷基和烷氧基；X和Z各自独立为CR11，Y从CR11和N中选择；R11为H或F；用于治疗与蛋白质错误折叠应激相关的疾病，特别是与错误折叠蛋白质积累相关的疾病。

  公开号：

  WO2014108520A1

文献信息

• Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
  申请人：GUEDAT Philippe

  公开号：US20160046589A1

  公开（公告）日：2016-02-18

  The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R 1 is alkyl, Cl, F or Br; R 2 is H or F; R 3 is selected from H and alkyl; R 4 is selected from H and C(O)R 6 ; R 5 is H; or R 4 and R 5 are linked to form a heterocyclic group which is optionally substituted with one or more R 10 groups; R 6 is selected from R 7 , OR 7 and NR 8 R 9 ; R 7 , R 8 and R 9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R 10 groups; each R 10 is independently selected from halogen, OH, CN, NO 2 , COO-alkyl, aralkyl, SO 2 -alkyl, SO 2 -aryl, COOH, CO-alkyl, CO-aryl, NH 2 , NH-alkyl, N(alkyl) 2 , CF 3 , alkyl and alkoxy; X and Z are each independently CR 11 , and Y is selected from CR 11 and N; and R 11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.

  本发明涉及式（I）的化合物，或其互变异构体和/或药学上可接受的盐，其中：R1为烷基，氯，氟或溴；R2为氢或氟；R3选自氢和烷基；R4选自氢和C（O）R6；R5为氢；或R4和R5连接形成一个杂环基团，该杂环基团可选地被一个或多个R10基团取代；R6选自R7，OR7和NR8R9；R7，R8和R9各自独立地选自烷基，环烷基，芳基烷基，环烯基，杂环基和芳基，每个基团可选地被一个或多个R10基团取代；每个R10各自独立地选自卤素，羟基，氰基，硝基，COO-烷基，芳基烷基，SO2-烷基，SO2-芳基，COOH，CO-烷基，CO-芳基，NH2，NH-烷基，N（烷基）2，CF3，烷基和烷氧基；X和Z各自独立地为CR11，Y选自CR11和N；R11为氢或氟；用于治疗与蛋白质错折应激相关的疾病，特别是与错折蛋白的积累相关的疾病。
• Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
  申请人：Medical Research Council

  公开号：US10100020B2

  公开（公告）日：2018-10-16

  The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.

  本发明涉及式(I)化合物或其同系物和/或药学上可接受的盐，其中：R1 是烷基、Cl、F 或 Br；R2 是 H 或 F；R3 选自 H 和烷基；R4 选自 H 和 C(O)R6；R5 是 H；或 R4 和 R5 连接形成杂环基团，该杂环基团任选被一个或多个 R10 基团取代；R6选自R7、OR7和NR8R9；R7、R8和R9各自独立地选自烷基、环烷基、芳基、环烯基、杂环烯基和芳基，其中每个基团都可选择被一个或多个R10基团取代；每个 R10 独立地选自卤素、OH、CN、NO2、COO-烷基、芳基、SO2-烷基、SO2-芳基、COOH、CO-烷基、CO-芳基、NH2、NH-烷基、N(烷基)2、CF3、烷基和烷氧基；X 和 Z 各自独立地为 CR11，Y 选自 CR11 和 N；R11 为 H 或 F；用于治疗与蛋白质错误折叠应激有关的疾病，特别是与错误折叠蛋白质的积累有关的疾病。
• BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES
  申请人：Medical Research Council

  公开号：EP2943467B1

  公开（公告）日：2016-07-13
• US9682943B2
  申请人：——

  公开号：US9682943B2

  公开（公告）日：2017-06-20
• [EN] BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES<br/>[FR] DÉRIVÉS DE BENZYLIDÈNEGUANIDINE ET LEUR UTILISATION THÉRAPEUTIQUE POUR LE TRAITEMENT DE MALADIES LIÉES À UN MAUVAIS REPLIEMENT DE PROTÉINES
  申请人：MEDICAL RES COUNCIL

  公开号：WO2014108520A1

  公开（公告）日：2014-07-17

  The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein:R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7,OR7and NR8R9; R7, R8and R9 are each independently selected from alkyl, cycloalkyl, aralkyl,cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2,COO-alkyl,aralkyl,SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy;X and Z are each independently CR11, and Y is selected from CR11and N; and R11is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.

  本发明涉及一种具有以下结构的化合物（I），或其亪式和/或药用可接受的盐，其中：R1为烷基，Cl，F或Br；R2为H或F；R3从H和烷基中选择；R4从H和C（O）R6中选择；R5为H；或R4和R5连接形成一个杂环基团，该基团可以选择性地用一个或多个R10基团取代；R6从R7，OR7和NR8R9中选择；R7，R8和R9分别独立选择自烷基，环烷基，芳基，环烯基，杂环烷基和芳基，每个基团可以选择性地用一个或多个R10基团取代；每个R10独立选择自卤素，OH，CN，NO2，COO-烷基，芳基，SO2-烷基，SO2-芳基，COOH，CO-烷基，CO-芳基，NH2，NH-烷基，N（烷基）2，CF3，烷基和烷氧基；X和Z各自独立为CR11，Y从CR11和N中选择；R11为H或F；用于治疗与蛋白质错误折叠应激相关的疾病，特别是与错误折叠蛋白质积累相关的疾病。